PDCD1 and hepatocellular carcinoma: According to a phase III clinical trial of atezo+bev combination therapy for HCC, the incidence of all grades and high-grade irAEs in patients treated with an atezo+bev combination was not significantly different from anti-PD-1 monotherapy or a PD-1 antibody plus CTLA-4 antibody combination [12].